1. 090 The effect of cladribine tablets on delaying the time to conversion to clinically definite multiple sclerosis (MS) or McDonald MS is consistent across subgroups in the ORACLE-MS study. (29th July 2019) Authors: Bowen, James; Gillett, Alan; Damian, Doris; Hyvert, Yann; Dangond, Fernando; Grosso, Megan; Leist, Thomas Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90(2019)e7 Page Start: A29 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of Ibudilast on MRI Measures in the Phase 2 SPRINT-MS Study. (26th January 2021) Authors: Naismith, Robert T.; Bermel, Robert A.; Coffey, Christopher S.; Goodman, Andrew D.; Fedler, Janel; Kearney, Marianne; Klawiter, Eric C.; Nakamura, Kunio; Narayanan, Sridar; Goebel, Christopher; Yankey, Jon; Klingner, Elizabeth; Fox, Robert J.; Shinnar, Shlomo; Ontaneda, Daniel; Riley, Claire S.; ... Journal: Neurology Issue: Volume 96:Number 4(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Randomized phase 2 trial of NP001–a novel immune regulator: Safety and early efficacy in ALS. Issue 3 (June 2015) Authors: Miller, Robert G.; Block, Gilbert; Katz, Jonathan S.; Barohn, Richard J.; Gopalakrishnan, Vidhya; Cudkowicz, Merit; Zhang, Jane R.; McGrath, Michael S.; Ludington, Elizabeth; Appel, Stan H.; Azhir, Ari; Katz, Jonathan; Kushner, Giovanna; Wong, Cynthia; Engel, Maguerite; Forshew, Dallas; Osborne, ... Journal: Neurology Issue: Volume 2:Issue 3(2015) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗